A Phase 3 interventional study of Abemaciclib and Erlotinib in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 231 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company — 6 open to participants now, 20 under way, 6 of them phase 3. Carcinoma, Non-Small-Cell Lung · Eli Lilly and Company.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 22nd largest by enrollment of the 139 interventional ones that give a count, is one of 3 that started in 2014, is one of 25 in phase 3, reaches primary completion later than 0 of the 19 other live ones, and was the 105th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →6 of the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 26 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, China and 5 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Austria and 26 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, France, Japan and 2 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 41 · Phase 2 86 · Phase 3 25 · Phase 4 3
First in 2000; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 453 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 109 across the 139 interventional studies, 1,076 across the 2 observational. Of the 121 that completed or were terminated, 81 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
5 of the studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT04956640Eli Lilly and CompanyStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | 2027-04 |
| NCT06465069Eli Lilly and CompanyA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | 2027-05 |
| NCT06561685Eli Lilly and CompanyA Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 milligrams (mg) abemaciclib administered, orally, every 12 hours plus best supportive care (BSC) on Days 1 to 28 (28 day cycles).
Drug: Abemaciclib
150 mg erlotinib administered, orally, every 24 hours plus BSC on Days 1 to 28 (28 day cycles).
Drug: Erlotinib
Administered orally
Also known as: LY2835219
Administered orally
Overall Survival (OS)
OS defined as from randomization date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
Time frame: From Randomization Date to Date of Death from Any Cause (Up to 32 Months)
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Time frame: From Randomization Date to Objective Progression (Up to 32 Months)
Progression Free Survival (PFS)
PFS defined as the from randomization date to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
Time frame: From Randomization Date until Disease Progression or Death from Any Cause (Up to 32 Months)
Change From Baseline in MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) Score
The MDASI-LC included 22 items + 3 additional trial-specific items, resulting in 6 collected and reported single-construct scores including core symptoms (13-item), interference (6-item), lung cancer (3-item), and trial-specific single outcomes for headache, diarrhea, and rash. A 2-construct composite core + lung cancer symptom (16-item) score was calculated. Data for all 7 scores were collected by an 11-point numeric rating scale anchored at 0 (not present or does not interfere) and 10 (as bad as you can imagine or interfered completely). The measurement range was 10 (maximum score-minimum score). Mixed Model Repeated Measure (MMRM) regression with covariates for treatment, visit, treatment\*visit, and baseline score predicted between-group Least Squares (LS) mean differences from baseline. Group-level negative change from baseline indicated group improvement.
Time frame: From Randomization Date through End of Study (Up to 32 Months)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval at Steady State
PK is determined by the area under the plasma concentration versus time curve during 1 dosing interval at steady state
Time frame: Day 1 of Cycle 1 through Cycle 3 (28 Day Cycles)
Change From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Score
There are 5 response levels on a good-to-bad continuum of 1-5 corresponding to none, slight, moderate, severe, and extreme/unable to. The EuroQol-developed crosswalk method was used to convert the EQ-5D-5L,using United Kingdom (UK) weights, health dimensions(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) into a single index value; the dimensions are not separately scored. The index is marked missing when ≥1 dimensions are missing. The index scores for the response patterns were anchored on full health to dead with negative values assigned to response patterns/health states considered worse than death. The best pattern is assigned the index value of 1.0; the worst pattern is assigned an index value of -0.594. Between-group differences in regression-predicted change from baseline score were estimated for the index. LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.
Time frame: From Randomization Date through End of Study (Up to 32 Months)
Resource Utilization: Percentage of Participants Who Are Hospitalized
Resource utilization is the percentage of participants who was hospitalized.
Time frame: From Randomization Date through End of Study (Up to 32 Months)
| Milestone | Abemaciclib | Erlotinib |
|---|---|---|
| Started | 270 | 183 |
| Received at least one dose of study drug | 265 | 175 |
| Off treatment | 246 | 172 |
| Death due to any cause | 30 | 20 |
| Progressive disease | 174 | 137 |
| Completed | 204 | 157 |
| Not completed | 66 | 26 |
| Withdrew: Adverse event | 32 | 4 |
| Withdrew: Withdrawal by subject | 13 | 16 |
| Withdrew: Noncompliance with study drug | 1 | 0 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: On treatment | 19 | 3 |
OS defined as from randomization date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
| months | Abemaciclib | Erlotinib |
|---|---|---|
| Overall Survival (OS) | 7.4 (6.5 to 8.8) | 7.8 (6.4 to 9.5) |
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
| percentage of participants | Abemaciclib | Erlotinib |
|---|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | 8.9 (5.5 to 12.3) | 2.7 (0.4 to 5.1) |
PFS defined as the from randomization date to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
| months | Abemaciclib | Erlotinib |
|---|---|---|
| Progression Free Survival (PFS) | 3.6 (2.8 to 3.8) | 1.9 (1.9 to 2.0) |
The MDASI-LC included 22 items + 3 additional trial-specific items, resulting in 6 collected and reported single-construct scores including core symptoms (13-item), interference (6-item), lung cancer (3-item), and trial-specific single outcomes for headache, diarrhea, and rash. A 2-construct composite core + lung cancer symptom (16-item) score was calculated. Data for all 7 scores were collected by an 11-point numeric rating scale anchored at 0 (not present or does not interfere) and 10 (as bad as you can imagine or interfered completely). The measurement range was 10 (maximum score-minimum score). Mixed Model Repeated Measure (MMRM) regression with covariates for treatment, visit, treatment\*visit, and baseline score predicted between-group Least Squares (LS) mean differences from baseline. Group-level negative change from baseline indicated group improvement.
| units on a scale | Abemaciclib | Erlotinib |
|---|---|---|
| Headache | 0.20 ± 0.11 | 0.27 ± 0.15 |
| Diarrhea | 1.91 ± 0.17 | 1.32 ± 0.23 |
| Rash | 0.65 ± 0.17 | 3.05 ± 0.22 |
| Mean Core Symptom Severity | 0.49 ± 0.10 | 0.73 ± 0.13 |
| Mean Interference | 0.70 ± 0.14 | 0.85 ± 0.18 |
| Mean Lung Cancer Symptom Severity | 0.16 ± 0.09 | 0.23 ± 0.12 |
| Mean Core Plus Lung Cancer Symptom Severity | 0.44 ± 0.09 | 0.65 ± 0.12 |
PK is determined by the area under the plasma concentration versus time curve during 1 dosing interval at steady state
| Hour*nanogram/milliliter (h*ng/mL) | Abemaciclib |
|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval at Steady State | 3350 ± 52 |
There are 5 response levels on a good-to-bad continuum of 1-5 corresponding to none, slight, moderate, severe, and extreme/unable to. The EuroQol-developed crosswalk method was used to convert the EQ-5D-5L,using United Kingdom (UK) weights, health dimensions(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) into a single index value; the dimensions are not separately scored. The index is marked missing when ≥1 dimensions are missing. The index scores for the response patterns were anchored on full health to dead with negative values assigned to response patterns/health states considered worse than death. The best pattern is assigned the index value of 1.0; the worst pattern is assigned an index value of -0.594. Between-group differences in regression-predicted change from baseline score were estimated for the index. LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.
| units on a scale | Abemaciclib | Erlotinib |
|---|---|---|
| Change From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Score | -0.08 ± 0.01 | -0.08 ± 0.02 |
Resource utilization is the percentage of participants who was hospitalized.
| percentage of participants | Abemaciclib | Erlotinib |
|---|---|---|
| Resource Utilization: Percentage of Participants Who Are Hospitalized | 40.4 | 22.9 |
Collected over From Baseline to End of Study (Up to 47 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abemaciclib | 186/265 (70.2%) | 112/265 (42.3%) | 247/265 (93.2%) |
| Erlotinib | 123/175 (70.3%) | 43/175 (24.6%) | 161/175 (92%) |
| Event | Abemaciclib | Erlotinib |
|---|---|---|
| PneumoniaInfections and infestations | 13/265 | 6/175 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/265 | 7/175 |
| DiarrhoeaGastrointestinal disorders | 10/265 | 0/175 |
| DehydrationMetabolism and nutrition disorders | 10/265 | 1/175 |
| Acute kidney injuryRenal and urinary disorders | 10/265 | 1/175 |
| NauseaGastrointestinal disorders | 7/265 | 0/175 |
| VomitingGastrointestinal disorders | 5/265 | 2/175 |
| AnaemiaBlood and lymphatic system disorders | 3/265 | 3/175 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 3/265 | 3/175 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/265 | 1/175 |
| Event | Abemaciclib | Erlotinib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 169/265 | 69/175 |
| Decreased appetiteMetabolism and nutrition disorders | 95/265 | 42/175 |
| NauseaGastrointestinal disorders | 94/265 | 30/175 |
| AnaemiaBlood and lymphatic system disorders | 87/265 | 23/175 |
| FatigueGeneral disorders | 73/265 | 29/175 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 1/265 | 46/175 |
| RashSkin and subcutaneous tissue disorders | 11/265 | 42/175 |
| VomitingGastrointestinal disorders | 61/265 | 15/175 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 53/265 | 22/175 |
| Blood creatinine increasedInvestigations | 45/265 | 2/175 |
| Age, Continuous(years) | Abemaciclib | Erlotinib | Total |
|---|---|---|---|
| Mean | 62.3 ± 8.9 | 62.9 ± 8.4 | 62.5 ± 8.7 |
| Sex: Female, Male(Participants) | Abemaciclib | Erlotinib | Total |
|---|---|---|---|
| Female | 107 | 74 | 181 |
| Male | 163 | 109 | 272 |
| Ethnicity (NIH/OMB)(Participants) | Abemaciclib | Erlotinib | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 12 | 25 |
| Not Hispanic or Latino | 197 | 132 | 329 |
| Unknown or Not Reported | 60 | 39 | 99 |
| Race (NIH/OMB)(Participants) | Abemaciclib | Erlotinib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 56 | 41 | 97 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 165 | 106 | 271 |
| More than one race | 3 | 1 | 4 |
| Unknown or Not Reported | 45 | 32 | 77 |
| Region of Enrollment(Participants) | Abemaciclib | Erlotinib | Total |
|---|---|---|---|
| Argentina | 1 | 2 | 3 |
| Romania | 7 | 7 | 14 |
| United States | 44 | 30 | 74 |
| Japan | 22 | 17 | 39 |
| Ukraine | 6 | 5 | 11 |
| Russia | 8 | 4 | 12 |
| Spain | 26 | 13 | 39 |
| Greece | 1 | 6 | 7 |
| Canada | 4 | 4 | 8 |
| Austria | 0 | 2 | 2 |
| South Korea | 13 | 13 | 26 |
| Turkey | 21 | 8 | 29 |
| China | 7 | 4 | 11 |
| Taiwan | 12 | 7 | 19 |
| Brazil | 7 | 5 | 12 |
| Poland | 6 | 2 | 8 |
| Italy | 5 | 12 | 17 |
| Israel | 5 | 1 | 6 |
| France | 35 | 32 | 67 |
| Germany | 30 | 14 | 44 |
Showing the first 100 of 231 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2014 to primary completion in Sep 2017, 35 months.
Results were first posted in Dec 2018, 1 year 2 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 35 months is below that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib
Carcinoma, Non-Small-Cell Lung →